Viridian Therapeutics (VRDN) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Viridian Therapeutics (VRDN) overview

Viridian Therapeutics (VRDN) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 70.8m and operating profit of USD -363m; the year-end share price was 31.12 USD and market capitalisation was USD 3,169m. Viridian Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Viridian Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 722mFY 2025
Share price31.12 USDFY 2025 year end
RevenueUSD 70.8mFY 2025
Operating profitUSD -363mFY 2025
Net earningsUSD -343mFY 2025
Market capitalisationUSD 3,169mFY 2025 year end

About Viridian Therapeutics

Viridian Therapeutics discovers, develops, and commercializes medicines for autoimmune and rare diseases, with a focus on thyroid eye disease. Its marketed product, Lumvoa (veligrotug-vvze), is an IGF-1R antagonist approved for TED. The company is advancing investigational elegrobart for TED, VRDN-008, a half-life-extended FcRn inhibitor, and a TSHR-targeting program for other autoimmune diseases.

Generate the Viridian Therapeutics report

Viridian Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Viridian Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Viridian Therapeutics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.